Monica Mita

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

Robert G. Maki, David R. D’Adamo, Mary Louise Keohan et al. · Journal of Clinical Oncology · 2009 · 573 citations · Full text

Medicine, Oncology, Cancer Pharmacology +15

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal et al. · JAMA Oncology · 2019 · 560 citations · Full text

Medicine, Oncology, Pharmacology +17

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

Masoud Tavazoie, Ilana Pollack, Raissa Tanqueco et al. · Cell · 2018 · 481 citations · Full text

Life Sciences, Immunology, Oncology +10

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

Shaveta Vinayak, Sara M. Tolaney, Lee S. Schwartzberg et al. · JAMA Oncology · 2019 · 433 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17